Market Overview

BofA Revives Myokardia With New Buy Rating

Share:
BofA Revives Myokardia With New Buy Rating
Related MYOK
The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt
The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet

Myokardia Inc (NASDAQ: MYOK) stock is up 290 percent year-over-year, but upcoming stimulants could drive additional outperformance, according to Bank of America Merrill Lynch. 

The Analyst

BofA's Tazeen Ahmad initiated coverage of Myokardia with a Buy rating and $71 price target.

The Thesis

The biotech’s candidates focus on two common cardiovascular diseases with no U.S.-approved therapies.

“We view MYOK’s focus in areas of undermet need which have relatively large addressable populations as providing meaningful upside leverage,” Ahmad said in a Tuesday note. (See the analyst's track record here.) 

Mavacamten demonstrated favorable tolerability and efficacy in a Phase 2 study in obstructive hypertrophic cardiomyopathy. A pivotal Phase 3 trial will begin this year and, by Ahmad's assessment, “should further validate MYOK’s platform.”

Sanofi SA (ADR) (NYSE: SNY)’s recent investment in Mavacamtem is a positive indicator for the drug’s prospects, the analyst said.

At the same time, the data is seen to derisk a parallel study in non-obstructive hypertrophic cardiomyopathy, which is expected to yield Phase 2 results in the second half of 2019.

“We believe both conditions could be underdiagnosed and note multiple opportunities for upside,” Ahmad said. 

The firm’s MYK-491 is seen to represent a more urgent need for a potentially broader population.

Considering Myokardia’s pipeline, BofA anticipates $200-million capital raises in 2019 and 2020 as the programs expand and forecast peak mavacamten sales of $1.5 billion.

Price Action

At the time of publication, Myokardia shares were trading up 2.74 percent at $54.35.

Related Links:

After Biogen's Alzheimer's Update, Wall Street Reacts

Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run

Latest Ratings for MYOK

DateFirmActionFromTo
Sep 2018Morgan StanleyInitiates Coverage OnOverweight
Aug 2018JP MorganMaintainsOverweightOverweight
Aug 2018Credit SuisseMaintainsOutperformOutperform

View More Analyst Ratings for MYOK
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill Lynch Tazeen AhmadAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (SNY + MYOK)

View Comments and Join the Discussion!

Earnings Preview For AngioDynamics

Casa Systems Is Oversold, Morgan Stanley Says In Upgrade